Evidence map›Paper›PMID 40695927›Full record

ArticleScientific reports2025

Antibiotic resistance profiles and risk factors of multidrug-resistant Escherichia coli in a large tertiary care hospital in a low- and middle-income country.

Nour Mousa, Banan M Aiesh, Ruba Jomaa, Yousef Zouneh, Ashraqat Namrouti, Adham Abutaha, Samah W Al-Jabi, Ali Sabateen, Sa'ed H Zyoud

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. MappingAntibiotics (Basel, Switzerland) · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nour MousaDepartment of Clinical and Community Pharmacy, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine.
Banan M AieshInfection Control Department, An-Najah National University Hospital, Nablus, 44839, Palestine. b.ayesh@najah.edu.
Ruba JomaaDepartment of Clinical and Community Pharmacy, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine.
Yousef ZounehDepartment of Clinical and Community Pharmacy, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine.
Ashraqat NamroutiInternal Medicine Department, An-Najah National University Hospital, Nablus, 44839, Palestine.
Adham AbutahaDepartment of Biomedical Sciences, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine.
Samah W Al-JabiDepartment of Clinical and Community Pharmacy, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine. samahjabi@yahoo.com.
Ali SabateenInfection Control Department, An-Najah National University Hospital, Nablus, 44839, Palestine.
Sa'ed H ZyoudDepartment of Clinical and Community Pharmacy, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine. saedzyoud@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Escherichia coli is a significant member of the Enterobacteriaceae family, a group of gram-negative rods that are normally found in the human gastrointestinal tract. The global rise of antimicrobial resistance presents a major and escalating threat to public health. In this context, our study sought to evaluate the patterns of antibiotic resistance and the risk factors associated with E. coli pathogens including multidrug-resistant (MDR) strians. We also aimed to determine the prevalence of MDR E. coli strains isolated from hospitalized patients to provide healthcare professionals with essential information for managing these infections. A retrospective hospital-based study was carried out at a major tertiary care facility between January 2022 and December 2023. Data on E. coli were obtained from the hospital's information system. The inclusion criteria were as follows: (1) patients of all ages, (2) both male and female, and (3) all types of E. coli isolated from any sample. Patients from outpatient clinics and hemodialysis centers, as well as 20 individuals whose medical records were incomplete, were excluded. As a result, the final sample consisted of 423 patients. The demographic, clinical, and microbiological characteristics of patients with E. coli infections were examined in this study. The mean age of the patients was 50.3 years, with no significant differences among the three subgroups of E. coli. The CR-E. coli group was more prevalent among males (64.4%, p = 0.031). Comorbidities, such as cardiovascular disease (43.8%), solid malignancies (32%), and diabetes (24.8%), did not significantly differ among the groups, with the exception of hematological malignancies (p = 0.016). In the CR-E. coli group, intubation was more prevalent (p = 0.006), indicating that there were substantial differences in medical procedures. The E. coli group presented the highest prevalence of urine cultures (47.9%), with substantial variations in resistance patterns among the species. The rates of resistance to cephalosporins and ciprofloxacin increased (67.7%). Renal disease (p = 0.035) was associated with MDR E. coli acquisition. The findings of this study revealed a considerable prevalence of MDR E. coli species causing various infections. As a result, antimicrobial stewardship programs that thoroughly assess the need for antibiotic use can help reduce the risk of resistance. Furthermore, implementing infection control measures is crucial in lowering the risk of cross transmission.

Indexed as

Anti-Bacterial AgentsDrug Resistance, Multiple, BacterialEscherichia coliEscherichia coli InfectionsAdultAgedFemaleHumansMaleMiddle AgedPrevalenceRetrospective StudiesRisk FactorsTertiary Care CentersAnti-Bacterial AgentsAntimicrobial resistanceE. coliMultidrug resistanceRisk factors

Identifiers

PMID40695927
PMCPMC12283929

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.